Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 2811.7 Crore for the year ended on 31st March, 2023, as against INR 2043.8 Crore for the last year, reflecting 37.6% growth. The net profit for the period, on a consolidated basis, was INR 715.3 Crore, as against INR 170.0 Crore last year.

The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years.

For the fourth quarter (Q4) ended March 31st, 2023, the company recorded a net revenue of INR 926.9 Crore, on a consolidated basis, as against INR 610.6 Crore during Q4, FY 2022. The profit for the fourth quarter, on a consolidated basis was INR 275.8 Crore, as against a loss of INR 50.5 Crore last year fourth quarter.

Segmental Revenue Split (All Figures in INR Crore)-

|  |  |  |
| --- | --- | --- |
| **Segment** | **Revenue, Q4 FY23** | **Revenue,**  **Full Year FY23** |
| API | 72.8 | 210.3 |
| Formulations, Domestic | 91.8 | 374.9 |
| Formulations, Exports (incl.  Profit Share & Foreign Subs) | 709.2 | 2063.2 |
| Other Operating income & non-operating income | 26.1 | 122.4 |
| Crop Health Sciences (CHS) | 27.0 | 40.9 |

*Image :*

